Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

alogliptin 6.25 MG Oral Tablet [Nesina]

Known as: ALOGLIPTIN BENZOATE 6.25 mg ORAL TABLET, FILM COATED [Nesina], Nesina 6.25 MG (as alogliptin benzoate 8.5 MG) Oral Tablet, Nesina 6.25 MG Oral Tablet 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND The aim of the present study was to evaluate serum nitric oxide (NO) and C reactive protein (CRP) concentration in… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 1
  • figure 5
2016
2016
A guide experimental design in chromatographic method development was described and applied successfully to the analysis of… Expand
Review
2015
Review
2015
The dipeptidyl peptidase-4 inhibitor alogliptin (Nesina®, Vipidia®) is approved in numerous countries worldwide for the treatment… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2014
2014
The single enantiomer drug, alogliptin (Alo, Nesina®) is a novel, orally available and selective dipeptidyl peptidase‐4 inhibitor… Expand
Review
2011
Review
2011
  • J. White
  • Drugs of today
  • 2011
  • Corpus ID: 31038561
The pharmacologic management of type 2 diabetes has changed dramatically in the past two decades. We have moved from a situation… Expand
Review
2011
Review
2011
Review
2010
Review
2010
Alogliptin (Nesina®) is a dipeptidyl peptidase-4 inhibitor that is approved in Japan for the treatment of adult patients with… Expand